The registry is an important step, along with TransCelerate’s Shared Investigator Platform, to streamlining some of the more inefficient clinical trial processes by allowing participating member companies to pool investigator data together into a centralized, cloud-based resource utilizing a universal identifier known as the DrugDev Golden Number.
This collaboration represents a significant step forward in the evolution of clinical trials and reflects how determined the industry is to make life easier for investigators and, ultimately, to make trials more efficient.
For pharmaceutical companies, the ability to expeditiously find investigator matches for their trials will drive improved performance—including faster study startup, faster patient recruitment, increased patient retention, enhanced operational efficiencies and reduced site failures and rescue sites.
For investigators, the registry expands their access to clinical trial opportunities by making them known throughout participating sponsors. Moreover, making their investigator and site profile information available in the registry reduces the number of basic site information requests, which in turn allows them to spend more time focused on clinical activities.
“The Investigator Registry represents a landmark revolution in how the industry works together and with investigators and sites, and we are very excited to introduce this opportunity to not only our members, but individual investigators and sites,” said Peter Milligan, vice president, clinical platforms transformation at GlaxoSmithKline and TransCelerate executive sponsor for the Investigator Registry initiative.
“The registry provides clinical operations professionals with the integrated data they need to make smart site selection decisions, and ensures sites have direct access to appropriate trial opportunities,” he said. “We are excited to embark on this partnership with DrugDev, given its focus on investigators, technology innovation and proven record developing solutions such as the Investigator Databank.”
“DrugDev is committed to helping sponsors and CROs capture meaningful efficiencies in clinical trial execution. This collaboration with TransCelerate will help to solve the problems that impede our ability to bring drugs to market faster,” said Elisa Cascade, president of data solutions at DrugDev.
Ibs Mahmood, DrugDev CEO, added, “Imagine a clinical trial universe where you as a study sponsor select an investigator or site anywhere in the world and instantly have direct access to a unified master record with reliable insights you’ve never enjoyed before. For the first time, you will have a comprehensive picture of a vast pool of investigators with the background and experience needed to work on a particular clinical trial. This technology has the potential to enable you to truly understand the investigators and sites running your trial. Thanks to TransCelerate’s Investigator Registry and the DrugDev Golden Number, as of today we are significantly closer to making this clinical trial universe a reality.”
Membership in TransCelerate is open to pharma and biotech companies with R&D operations. Executive offices are located in Philadelphia, Pa.
DrugDev is a technology company that provides cloud-based solutions to help sponsors, CROs and investigators conduct more clinical trials together. Built around a global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations.